VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The SURPASS-ET study: evaluating novel treatment approaches in ET

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into current treatment approaches in essential thrombocythemia (ET), and further discusses the main aims of the SURPASS-ET trial (NCT04285086), which is comparing the use of ropeginterferon alfa-2b versus anagrelide in patients with ET. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter